{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:49Z","timestamp":1792783369091,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza","id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct oral anticoagulants (DOACs) reduce thromboembolism in atrial fibrillation (AF), but their effect on cardiac outcomes is less studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic review and network meta-analysis were performed on AF patients on DOACs\/vitamin K antagonists (VKAs). Both observational studies and randomized clinical trials (RCTs) were included. Endpoints were myocardial infarction (MI) and major adverse cardiac events (MACE). Rankograms and SUCRA were performed. Sub-group analysis included age (&lt;\/\u2265\u200975\u00a0years) and length of follow-up (&lt;\/\u2265\u200912\u00a0months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>50 studies (3 RCTs, 4 post hoc analyses of RCTs and 43 observational studies) with 1,769,987 patients were included (59.9% on DOACs and 45.3% women).<\/jats:p>\n                    <jats:p>The MI risk (46 studies with 1,554,704 patients) was lower in all DOACs compared to VKA (apixaban: hazard ratio [HR] 0.83, 95% credible interval [95%CI 0.72\u20130.96], edoxaban: HR 0.68, 95%CI 0.53\u20130.86, rivaroxaban: HR 0.84, 95%CI 0.74\u20130.95, dabigatran: HR 0.85, 95%CI 0.75\u20130.97). SUCRA showed edoxaban as first choice for preventing MI overall. In patients aged\u2009&lt;\u200975\u00a0years, a lower MI risk was found for edoxaban (HR 0.60, 95%CI 0.41\u20130.85), while in those aged\u2009\u2265\u200975\u00a0years, no significant difference was found among anticoagulants. Heterogeneity was low in all analyses. Network meta-analysis showed no differences among DOACs.<\/jats:p>\n                    <jats:p>Compared to VKA, apixaban (HR 0.77, 95%CI 0.63\u20130.97) was associated with lower MACE risk. Analysis of SUCRA showed apixaban as first choice for preventing MACE overall and in patients treated for\u2009&lt;\u200912\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DOACs were associated with a lower risk of MACE\/MI in AF. The effect of DOACs on cardiovascular risk differs according to aging and follow-up length. However, our findings are based on indirect evidence, and further studies are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42023407778.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11739-026-04480-1","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:36:53Z","timestamp":1785775013000},"page":"2305-2320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of direct oral anticoagulants on cardiac outcomes in atrial fibrillation: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"21","author":[{"given":"Danilo","family":"Menichelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Malatesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pannunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Farcomeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Violi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"4480_CR1","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D, Group ESCSD (2024) 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45:3314\u20133414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"key":"4480_CR2","doi-asserted-by":"publisher","first-page":"f11","DOI":"10.1093\/ehjcvp\/pvab002","volume":"7","author":"D Menichelli","year":"2021","unstructured":"Menichelli D, Del Sole F, Di Rocco A, Farcomeni A, Vestri A, Violi F, Pignatelli P, Lip GYH, Pastori D (2021) Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. Eur Heart J Cardiovasc Pharmacother 7:f11\u2013f19. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab002","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4480_CR3","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamaneurol.2025.1337","volume":"82","author":"JJ McCabe","year":"2025","unstructured":"McCabe JJ, Cheung Y, Foley M, Brennan SO, Buckley J, Renom PC, Cassidy T, Collins R, Dolan E, Grosse GM, Harbison J, James K, Khadjooi K, Induruwa I, Katan M, Maher S, O\u2019Connor M, O\u2019Donnell M, Purroy F, Synott P, Kelly PJ (2025) Residual risk of recurrent stroke despite anticoagulation in patients with atrial fibrillation: a systematic review and meta-analysis. JAMA Neurol 82:696\u2013705. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1337","journal-title":"JAMA Neurol"},{"key":"4480_CR4","doi-asserted-by":"publisher","first-page":"101117","DOI":"10.1016\/j.jacadv.2024.101117","volume":"3","author":"D Menichelli","year":"2024","unstructured":"Menichelli D, Pignatelli P, Brogi T, Pannunzio A, Violi F, Lip GYH, Pastori D, Group A-AS (2024) Incidence of all-cause, cardiovascular, and atrial fibrillation-related hospitalizations: focus on antiarrhythmic drugs. JACC Adv 3:101117. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101117","journal-title":"JACC Adv"},{"key":"4480_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/ehjqcco\/qcw019","volume":"2","author":"M Janzon","year":"2016","unstructured":"Janzon M, Henriksson M, Hasvold P, Hjelm H, Thuresson M, Jernberg T (2016) Long-term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting: results from a contemporary nationwide registry study. Eur Heart J Qual Care Clin Outcomes 2:291\u2013298. https:\/\/doi.org\/10.1093\/ehjqcco\/qcw019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"4480_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13061-4","volume":"7","author":"HY Lee","year":"2017","unstructured":"Lee HY, Yang PS, Kim TH, Uhm JS, Pak HN, Lee MH, Joung B (2017) Atrial fibrillation and the risk of myocardial infarction: a nation-wide propensity-matched study. Sci Rep 7:12716. https:\/\/doi.org\/10.1038\/s41598-017-13061-4","journal-title":"Sci Rep"},{"key":"4480_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamainternmed.2013.11912","volume":"174","author":"EZ Soliman","year":"2014","unstructured":"Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, Thacker EL, Judd S, Howard VJ, Howard G, Herrington DM, Cushman M (2014) Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 174:107\u2013114. https:\/\/doi.org\/10.1001\/jamainternmed.2013.11912","journal-title":"JAMA Intern Med"},{"key":"4480_CR8","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","volume":"120","author":"L Staerk","year":"2017","unstructured":"Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH (2017) Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res 120:1501\u20131517. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.309732","journal-title":"Circ Res"},{"key":"4480_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/eurheartj\/eht483","volume":"35","author":"JP Piccini","year":"2014","unstructured":"Piccini JP, Hammill BG, Sinner MF, Hernandez AF, Walkey AJ, Benjamin EJ, Curtis LH, Heckbert SR (2014) Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. Eur Heart J 35:250\u2013256. https:\/\/doi.org\/10.1093\/eurheartj\/eht483","journal-title":"Eur Heart J"},{"key":"4480_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003347","author":"F Violi","year":"2016","unstructured":"Violi F, Soliman EZ, Pignatelli P, Pastori D (2016) Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.003347","journal-title":"J Am Heart Assoc"},{"key":"4480_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","volume":"362","author":"Olsson SB, Executive Steering Committee of the SIIII","year":"2003","unstructured":"Olsson SB, Executive Steering Committee of the SIIII (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691\u20131698","journal-title":"Lancet"},{"key":"4480_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ijcard.2015.08.054","volume":"201","author":"D Pastori","year":"2015","unstructured":"Pastori D, Pignatelli P, Saliola M, Carnevale R, Vicario T, Del Ben M, Cangemi R, Barilla F, Lip GY, Violi F (2015) Inadequate anticoagulation by vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation. Int J Cardiol 201:513\u2013516. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.054","journal-title":"Int J Cardiol"},{"key":"4480_CR13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.mayocp.2020.06.057","volume":"96","author":"D Pastori","year":"2021","unstructured":"Pastori D, Menichelli D, Del Sole F, Pignatelli P, Violi F, group A-As (2021) Long-term risk of major adverse cardiac events in atrial fibrillation patients on direct oral anticoagulants. Mayo Clin Proc 96:658\u2013665. https:\/\/doi.org\/10.1016\/j.mayocp.2020.06.057","journal-title":"Mayo Clin Proc"},{"key":"4480_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.pcad.2015.12.001","volume":"58","author":"A Tornyos","year":"2016","unstructured":"Tornyos A, Kehl D, D\u2019Ascenzo F, Komocsi A (2016) Risk of myocardial infarction in patients with long-term non-vitamin K antagonist oral anticoagulant treatment. Prog Cardiovasc Dis 58:483\u2013494. https:\/\/doi.org\/10.1016\/j.pcad.2015.12.001","journal-title":"Prog Cardiovasc Dis"},{"key":"4480_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4480_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"4480_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4480_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"4480_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13643-025-02752-z","volume":"14","author":"JF Tierney","year":"2025","unstructured":"Tierney JF, Burdett S, Fisher DJ (2025) Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance. Syst Rev 14:84. https:\/\/doi.org\/10.1186\/s13643-025-02752-z","journal-title":"Syst Rev"},{"key":"4480_CR20","doi-asserted-by":"publisher","first-page":"5473240","DOI":"10.1155\/2019\/5473240","volume":"2019","author":"V Russo","year":"2019","unstructured":"Russo V, Rago A, Proietti R, Attena E, Rainone C, Crisci M, Papa AA, Calabro P, D\u2019Onofrio A, Golino P, Nigro G (2019) Safety and efficacy of triple antithrombotic therapy with dabigatran versus vitamin K antagonist in atrial fibrillation patients: a pilot study. Biomed Res Int 2019:5473240. https:\/\/doi.org\/10.1155\/2019\/5473240","journal-title":"Biomed Res Int"},{"key":"4480_CR21","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423\u20132434. https:\/\/doi.org\/10.1056\/NEJMoa1611594","journal-title":"N Engl J Med"},{"key":"4480_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/08971900231202643","author":"KT Burnham","year":"2023","unstructured":"Burnham KT, Yang T, Wooster J (2023) A real-world comparison of apixaban and rivaroxaban in obese and morbidly obese patients with nonvalvular atrial fibrillation. J Pharm Pract. https:\/\/doi.org\/10.1177\/08971900231202643","journal-title":"J Pharm Pract"},{"key":"4480_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 394:1335\u20131343. https:\/\/doi.org\/10.1016\/S0140-6736(19)31872-0","journal-title":"Lancet"},{"key":"4480_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"4480_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejim.2020.12.011","volume":"85","author":"D Pastori","year":"2021","unstructured":"Pastori D, Menichelli D, Violi F, Pignatelli P, G YHL, group A-As, (2021) The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. Eur J Intern Med 85:80\u201385. https:\/\/doi.org\/10.1016\/j.ejim.2020.12.011","journal-title":"Eur J Intern Med"},{"key":"4480_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11040111","author":"G Renda","year":"2024","unstructured":"Renda G, Bucciarelli V, Barbieri G, Lanuti P, Berteotti M, Malatesta G, Cesari F, Salvatore T, Giusti B, Gori AM, Marcucci R, De Caterina R (2024) Ex vivo antiplatelet effects of oral anticoagulants. J Cardiovasc Dev Dis. https:\/\/doi.org\/10.3390\/jcdd11040111","journal-title":"J Cardiovasc Dev Dis"},{"key":"4480_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bcp.2019.02.016","volume":"163","author":"V Cammisotto","year":"2019","unstructured":"Cammisotto V, Carnevale R, Nocella C, Stefanini L, Bartimoccia S, Coluccia A, Silvestri R, Pignatelli P, Pastori D, Violi F (2019) Nox2-mediated platelet activation by glycoprotein (GP) VI: effect of rivaroxaban alone and in combination with aspirin. Biochem Pharmacol 163:111\u2013118. https:\/\/doi.org\/10.1016\/j.bcp.2019.02.016","journal-title":"Biochem Pharmacol"},{"key":"4480_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1055\/a-2483-0107","volume":"125","author":"TL Lindahl","year":"2025","unstructured":"Lindahl TL, Kumar AP, Hallstrom T, Al-Hashimi A, du Rietz A, Arlaman E, Uvdal K, Macwan AS (2025) Dabigatran attenuates the binding of thrombin to platelets-a novel mechanism of action. Thromb Haemost 125:747\u2013756. https:\/\/doi.org\/10.1055\/a-2483-0107","journal-title":"Thromb Haemost"},{"key":"4480_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.thromres.2019.10.007","volume":"183","author":"G Jourdi","year":"2019","unstructured":"Jourdi G, Bachelot-Loza C, Mazoyer E, Poirault-Chassac S, Duchemin J, Fontenay M, Gaussem P (2019) Effect of rivaroxaban and dabigatran on platelet functions: in vitro study. Thromb Res 183:159\u2013162. https:\/\/doi.org\/10.1016\/j.thromres.2019.10.007","journal-title":"Thromb Res"},{"key":"4480_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171486","volume":"12","author":"L Pujadas-Mestres","year":"2017","unstructured":"Pujadas-Mestres L, Lopez-Vilchez I, Arellano-Rodrigo E, Reverter JC, Lopez-Farre A, Diaz-Ricart M, Badimon JJ, Escolar G (2017) Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: studies with circulating blood and in a platelet-based model of thrombin generation. PLoS ONE 12:e0171486. https:\/\/doi.org\/10.1371\/journal.pone.0171486","journal-title":"PLoS ONE"},{"key":"4480_CR31","doi-asserted-by":"publisher","first-page":"107602962094858","DOI":"10.1177\/1076029620948585","volume":"26","author":"J Sokol","year":"2020","unstructured":"Sokol J, Nehaj F, Ivankova J, Mokan M, Lisa L, Zolkova J, Vadelova L, Mokan M, Stasko J (2020) Impact of edoxaban on thrombin-dependent platelet aggregation. Clin Appl Thrombosis 26:1076029620948585. https:\/\/doi.org\/10.1177\/1076029620948585","journal-title":"Clin Appl Thrombosis"},{"key":"4480_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","volume":"125","author":"SH Hohnloser","year":"2012","unstructured":"Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125:669\u2013676. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.055970","journal-title":"Circulation"},{"key":"4480_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.006511","volume":"13","author":"K Vilain","year":"2020","unstructured":"Vilain K, Li H, Kwong WJ, Antman EM, Ruff CT, Braunwald E, Cohen DJ, Giugliano RP, Magnuson EA, Investigators EA-TT (2020) Cardiovascular- and bleeding-related hospitalization rates with edoxaban versus warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. Circ Cardiovasc Qual Outcomes 13:e006511. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.120.006511","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"4480_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijcard.2013.10.062","volume":"170","author":"MC Bahit","year":"2013","unstructured":"Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, Aylward PE, Verheugt FW, Keltai M, Diaz R, Hanna M, Granger CB, Wallentin L (2013) Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol 170:215\u2013220. https:\/\/doi.org\/10.1016\/j.ijcard.2013.10.062","journal-title":"Int J Cardiol"},{"key":"4480_CR35","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","volume":"61","author":"TB Larsen","year":"2013","unstructured":"Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY (2013) Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61:2264\u20132273. https:\/\/doi.org\/10.1016\/j.jacc.2013.03.020","journal-title":"J Am Coll Cardiol"},{"key":"4480_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","volume":"131","author":"DJ Graham","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA (2015) Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 131:157\u2013164. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.012061","journal-title":"Circulation"},{"key":"4480_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001798","author":"JC Lauffenburger","year":"2015","unstructured":"Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G (2015) Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.115.001798","journal-title":"J Am Heart Assoc"},{"key":"4480_CR38","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1160\/TH15-06-0497","volume":"114","author":"JD Seeger","year":"2015","unstructured":"Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S (2015) Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 114:1277\u20131289. https:\/\/doi.org\/10.1160\/TH15-06-0497","journal-title":"Thromb Haemost"},{"key":"4480_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/STROKEAHA.115.011476","volume":"47","author":"YH Chan","year":"2016","unstructured":"Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, Tu HT, Yeh YH, Kuo CT (2016) Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. Stroke 47:441\u2013449. https:\/\/doi.org\/10.1161\/STROKEAHA.115.011476","journal-title":"Stroke"},{"key":"4480_CR40","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1160\/TH15-06-0453","volume":"114","author":"TC Villines","year":"2015","unstructured":"Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E (2015) A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 114:1290\u20131298. https:\/\/doi.org\/10.1160\/TH15-06-0453","journal-title":"Thromb Haemost"},{"key":"4480_CR41","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.hlc.2017.04.002","volume":"27","author":"CI Coleman","year":"2018","unstructured":"Coleman CI, Peacock WF, Antz M (2018) Comparative effectiveness and safety of apixaban and vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation treated in routine German practice. Heart Lung Circ 27:390\u2013393. https:\/\/doi.org\/10.1016\/j.hlc.2017.04.002","journal-title":"Heart Lung Circ"},{"key":"4480_CR42","doi-asserted-by":"publisher","first-page":"845","DOI":"10.7326\/M16-1157","volume":"167","author":"AS Go","year":"2017","unstructured":"Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ (2017) Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med 167:845\u2013854. https:\/\/doi.org\/10.7326\/M16-1157","journal-title":"Ann Intern Med"},{"key":"4480_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005362","author":"CL Lai","year":"2017","unstructured":"Lai CL, Chen HM, Liao MT, Lin TT, Chan KA (2017) Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.005362","journal-title":"J Am Heart Assoc"},{"key":"4480_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12872-017-0672-5","volume":"17","author":"FL Norby","year":"2017","unstructured":"Norby FL, Bengtson LGS, Lutsey PL, Chen LY, MacLehose RF, Chamberlain AM, Rapson I, Alonso A (2017) Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 17:238. https:\/\/doi.org\/10.1186\/s12872-017-0672-5","journal-title":"BMC Cardiovasc Disord"},{"key":"4480_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006381","author":"G Palamaner Subash Shantha","year":"2017","unstructured":"Palamaner Subash Shantha G, Mentias A, Inampudi C, Kumar AA, Chaikriangkrai K, Bhise V, Deshmukh A, Patel N, Pancholy S, Horwitz PA, Mickelsen S, Bhave PD, Giudici M, Oral H, Vaughan Sarrazin MS (2017) Sex-specific associations of oral anticoagulant use and cardiovascular outcomes in patients with atrial fibrillation. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.006381","journal-title":"J Am Heart Assoc"},{"key":"4480_CR46","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1161\/STROKEAHA.118.021387","volume":"49","author":"HT Yu","year":"2018","unstructured":"Yu HT, Yang PS, Kim TH, Jang E, Kim D, Uhm JS, Kim JY, Pak HN, Lee MH, Lip GYH, Joung B (2018) Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation. Stroke 49:2421\u20132429. https:\/\/doi.org\/10.1161\/STROKEAHA.118.021387","journal-title":"Stroke"},{"key":"4480_CR47","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/jgs.15430","volume":"66","author":"CL Lai","year":"2018","unstructured":"Lai CL, Chen HM, Liao MT, Lin TT (2018) Dabigatran, rivaroxaban, and warfarin in the oldest adults with atrial fibrillation in Taiwan. J Am Geriatr Soc 66:1567\u20131574. https:\/\/doi.org\/10.1111\/jgs.15430","journal-title":"J Am Geriatr Soc"},{"key":"4480_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacc.2018.04.036","volume":"72","author":"CJ Lee","year":"2018","unstructured":"Lee CJ, Gerds TA, Carlson N, Bonde AN, Gislason GH, Lamberts M, Olesen JB, Pallisgaard JL, Hansen ML, Torp-Pedersen C (2018) Risk of myocardial infarction in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 72:17\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.036","journal-title":"J Am Coll Cardiol"},{"key":"4480_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijcard.2017.06.110","volume":"257","author":"AS Barnett","year":"2018","unstructured":"Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP (2018) Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: results from ROCKET AF. Int J Cardiol 257:78\u201383. https:\/\/doi.org\/10.1016\/j.ijcard.2017.06.110","journal-title":"Int J Cardiol"},{"key":"4480_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.thromres.2018.05.022","volume":"167","author":"S Sjalander","year":"2018","unstructured":"Sjalander S, Sjogren V, Renlund H, Norrving B, Sjalander A (2018) Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res 167:113\u2013118. https:\/\/doi.org\/10.1016\/j.thromres.2018.05.022","journal-title":"Thromb Res"},{"key":"4480_CR51","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008773","author":"A Briasoulis","year":"2018","unstructured":"Briasoulis A, Inampudi C, Akintoye E, Alvarez P, Panaich S, Vaughan-Sarrazin M (2018) Safety and efficacy of novel oral anticoagulants versus warfarin in Medicare beneficiaries with atrial fibrillation and valvular heart disease. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.118.008773","journal-title":"J Am Heart Assoc"},{"key":"4480_CR52","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijcard.2018.03.063","volume":"261","author":"HF Lee","year":"2018","unstructured":"Lee HF, Chan YH, Tu HT, Kuo CT, Yeh YH, Chang SH, Wu LS, See LC (2018) The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation. Int J Cardiol 261:78\u201383. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.063","journal-title":"Int J Cardiol"},{"key":"4480_CR53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/bcp.13814","volume":"85","author":"T Mueller","year":"2019","unstructured":"Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M (2019) Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol 85:422\u2013431. https:\/\/doi.org\/10.1111\/bcp.13814","journal-title":"Br J Clin Pharmacol"},{"key":"4480_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026486","volume":"9","author":"NL Pratt","year":"2019","unstructured":"Pratt NL, Ramsay E, Kalisch Ellett LM, Duszynski K, Shakib S, Kerr M, Caughey G, Roughead EE (2019) Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study. BMJ Open 9:e026486. https:\/\/doi.org\/10.1136\/bmjopen-2018-026486","journal-title":"BMJ Open"},{"key":"4480_CR55","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s11239-019-01838-5","volume":"48","author":"A Amin","year":"2019","unstructured":"Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL (2019) Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. J Thromb Thrombolysis 48:240\u2013249. https:\/\/doi.org\/10.1007\/s11239-019-01838-5","journal-title":"J Thromb Thrombolysis"},{"key":"4480_CR56","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1111\/dom.13787","volume":"21","author":"WL Baker","year":"2019","unstructured":"Baker WL, Beyer-Westendorf J, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI (2019) Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. Diabetes Obes Metab 21:2107\u20132114. https:\/\/doi.org\/10.1111\/dom.13787","journal-title":"Diabetes Obes Metab"},{"key":"4480_CR57","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","volume":"40","author":"J Oldgren","year":"2019","unstructured":"Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP (2019) Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J 40:1553\u20131562. https:\/\/doi.org\/10.1093\/eurheartj\/ehz059","journal-title":"Eur Heart J"},{"key":"4480_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12933-020-01043-2","volume":"19","author":"YH Chan","year":"2020","unstructured":"Chan YH, Lee HF, Li PR, Liu JR, Chao TF, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC, Lip GYH (2020) Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. Cardiovasc Diabetol 19:63. https:\/\/doi.org\/10.1186\/s12933-020-01043-2","journal-title":"Cardiovasc Diabetol"},{"key":"4480_CR59","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/ehjcvp\/pvz047","volume":"6","author":"CI Coleman","year":"2020","unstructured":"Coleman CI, Baker WL, Meinecke AK, Eriksson D, Martinez BK, Bunz TJ, Alberts MJ (2020) Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. Eur Heart J Cardiovasc Pharmacother 6:159\u2013166. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz047","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4480_CR60","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1182\/bloodadvances.2022009099","volume":"7","author":"AB Ingason","year":"2023","unstructured":"Ingason AB, Hreinsson JP, Agustsson AS, Lund SH, Rumba E, Palsson DA, Reynisson IE, Gudmundsdottir BR, Onundarson PT, Bjornsson ES (2023) Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score-weighted study. Blood Adv 7:2564\u20132572. https:\/\/doi.org\/10.1182\/bloodadvances.2022009099","journal-title":"Blood Adv"},{"key":"4480_CR61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10557-020-07126-2","volume":"35","author":"A Briasoulis","year":"2021","unstructured":"Briasoulis A, Mentias A, Mazur A, Alvarez P, Leira EC, Vaughan Sarrazin MS (2021) Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation. Cardiovasc Drugs Ther 35:261\u2013272. https:\/\/doi.org\/10.1007\/s10557-020-07126-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"4480_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2021.02.021","volume":"148","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Thomas L, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Friend K, Mardekian J, Pan X, Yuce H, Jones WS (2021) Clinical and economic outcomes among nonvalvular atrial fibrillation patients with coronary artery disease and\/or peripheral artery disease. Am J Cardiol 148:69\u201377. https:\/\/doi.org\/10.1016\/j.amjcard.2021.02.021","journal-title":"Am J Cardiol"},{"key":"4480_CR63","first-page":"353","volume":"23","author":"A Elis","year":"2021","unstructured":"Elis A, Klempfner R, Gurevitz C, Gilady E, Goldenberg I (2021) Apixaban in patients with atrial fibrillation and severe renal dysfunction: findings from a national registry. Isr Med Assoc J 23:353\u2013358","journal-title":"Isr Med Assoc J"},{"key":"4480_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194536","author":"E Crocetti","year":"2021","unstructured":"Crocetti E, Cattaneo S, Bergamaschi W, De Servi S, Russo AG (2021) Effectiveness and safety of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: results of a real-world study in a metropolitan area of Northern Italy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10194536","journal-title":"J Clin Med"},{"key":"4480_CR65","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.amjmed.2020.06.003","volume":"133","author":"RD Lopes","year":"2020","unstructured":"Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS (2020) Corrigendum to \u201cEffectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary\/Peripheral Artery Disease\u201d American Journal of Medicine 131:09 (2018): 1074-1085.e4. Am J Med 133:1229\u20131238. https:\/\/doi.org\/10.1016\/j.amjmed.2020.06.003","journal-title":"Am J Med"},{"key":"4480_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.803233","volume":"9","author":"PH Liu","year":"2022","unstructured":"Liu PH, Liu ZH, Niu MH, Chen P, Shi YB, He F, Guo R (2022) A comparative study of the clinical benefits of rivaroxaban and warfarin in patients with non-valvular atrial fibrillation with high bleeding risk. Front Cardiovasc Med 9:803233. https:\/\/doi.org\/10.3389\/fcvm.2022.803233","journal-title":"Front Cardiovasc Med"},{"key":"4480_CR67","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00392-022-01996-2","volume":"111","author":"GYH Lip","year":"2022","unstructured":"Lip GYH, Kotalczyk A, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Marler S, Gurusamy VK, Huisman MV, Investigators G-A (2022) Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF registry. Clin Res Cardiol 111:560\u2013573. https:\/\/doi.org\/10.1007\/s00392-022-01996-2","journal-title":"Clin Res Cardiol"},{"key":"4480_CR68","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.cjco.2022.01.002","volume":"4","author":"LA Boivin-Proulx","year":"2022","unstructured":"Boivin-Proulx LA, Potter BJ, Dorais M, Perreault S (2022) Comparative effectiveness and safety of direct oral anticoagulants vs warfarin among obese patients with atrial fibrillation. CJC Open 4:395\u2013405. https:\/\/doi.org\/10.1016\/j.cjco.2022.01.002","journal-title":"CJC Open"},{"key":"4480_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.978639","volume":"9","author":"Q Yu","year":"2022","unstructured":"Yu Q, Chen C, Xu J, Xiao Y, Bao J, Yuan L (2022) Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization. Front Cardiovasc Med 9:978639. https:\/\/doi.org\/10.3389\/fcvm.2022.978639","journal-title":"Front Cardiovasc Med"},{"key":"4480_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064662","volume":"12","author":"A Jaksa","year":"2022","unstructured":"Jaksa A, Gibbs L, Kent S, Rowark S, Duffield S, Sharma M, Kincaid L, Ali AK, Patrick AR, Govil P, Jonsson P, Gatto N (2022) Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study. BMJ Open 12:e064662. https:\/\/doi.org\/10.1136\/bmjopen-2022-064662","journal-title":"BMJ Open"},{"key":"4480_CR71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/ehjcvp\/pvac063","volume":"9","author":"Y Talmor-Barkan","year":"2022","unstructured":"Talmor-Barkan Y, Yacovzada NS, Rossman H, Witberg G, Kalka I, Kornowski R, Segal E (2022) Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial. Eur Heart J Cardiovasc Pharmacother 9:26\u201337. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac063","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4480_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1125576","volume":"14","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, De Backer TL, Bertels X, Steurbaut S, Lahousse L (2023) Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: a nationwide cohort study. Front Pharmacol 14:1125576. https:\/\/doi.org\/10.3389\/fphar.2023.1125576","journal-title":"Front Pharmacol"},{"key":"4480_CR73","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.xjon.2023.05.006","volume":"15","author":"MP Pereira","year":"2023","unstructured":"Pereira MP, Lima EG, Pitta FG, Gowdak LHW, Mioto BM, Carvalho LNS, Darrieux F, Mejia OAV, Jatene FB, Serrano CV Jr. (2023) Rivaroxaban versus warfarin in postoperative atrial fibrillation: cost-effectiveness analysis in a single-center, randomized, and prospective trial. JTCVS Open 15:199\u2013210. https:\/\/doi.org\/10.1016\/j.xjon.2023.05.006","journal-title":"JTCVS Open"},{"key":"4480_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100813","volume":"3","author":"R Kreutz","year":"2024","unstructured":"Kreutz R, Deray G, Floege J, Gwechenberger M, Hahn K, Luft AR, Persson P, Axthelm C, Beer JH, Bergler-Klein J, Lellouche N, Taggeselle J, Coleman CI, Beyer-Westendorf J, registry X (2024) Rivaroxaban vs vitamin K antagonist in patients with atrial fibrillation and advanced chronic kidney disease. JACC Adv 3:100813. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100813","journal-title":"JACC Adv"},{"key":"4480_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1445970","volume":"11","author":"P Liu","year":"2024","unstructured":"Liu P (2024) A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk. Front Cardiovasc Med 11:1445970. https:\/\/doi.org\/10.3389\/fcvm.2024.1445970","journal-title":"Front Cardiovasc Med"},{"key":"4480_CR76","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/ehjcvp\/pvaf063","volume":"11","author":"L Dari","year":"2025","unstructured":"Dari L, Beradid S, Constans J, Pariente A, Renoux C (2025) Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease. Eur Heart J Cardiovasc Pharmacother 11:664\u2013673. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf063","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4480_CR77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/23969873241274598","volume":"10","author":"CW Fang","year":"2025","unstructured":"Fang CW, Hsieh CY, Yang HY, Tsai CF, Sung SF (2025) Comparative effectiveness and safety of direct oral anticoagulants and warfarin in atrial fibrillation patients with dementia. Eur Stroke J 10:128\u2013136. https:\/\/doi.org\/10.1177\/23969873241274598","journal-title":"Eur Stroke J"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04480-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04480-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04480-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:33:51Z","timestamp":1789540431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04480-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4480"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04480-1","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","label":"Human and animal rights statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}